Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Clinical trial NCT04181788 · COMPLETED

Trial details

NCT number: NCT04181788
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Malignancies Non-small-cell Lung Cancer

Start date: 2020-03-18
Primary completion: 2022-03-03
Enrollment: 155

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.